Survival Up With Bortezomib in T-Cell Lymphoblastic Lymphoma
No differences in EFS or OS seen with/without bortezomib overall or in patients with T-cell acute lymphoblastic leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.